PubRank

Snorri S Thorgeirsson

Author PubWeight™ 172.18‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004 6.98
2 A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006 6.31
3 Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 2004 4.17
4 Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004 3.97
5 Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006 3.95
6 Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006 3.95
7 Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2011 2.63
8 A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010 2.59
9 Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007 2.53
10 Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 2012 2.40
11 Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002 2.38
12 GTF2IRD1 in craniofacial development of humans and mice. Science 2005 2.15
13 DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 2007 2.09
14 Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 2004 2.06
15 Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2010 2.05
16 Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008 2.04
17 Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 2010 2.03
18 Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2006 1.98
19 DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004 1.90
20 Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut 2013 1.89
21 Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008 1.87
22 Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 2010 1.82
23 Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 2013 1.76
24 DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 2003 1.76
25 Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 2011 1.74
26 Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004 1.71
27 Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2011 1.68
28 Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 2004 1.65
29 Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol 2009 1.60
30 Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012 1.57
31 Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 2002 1.57
32 Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene 2003 1.52
33 Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002 1.51
34 Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009 1.50
35 DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 2005 1.45
36 Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009 1.45
37 Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 2007 1.43
38 Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012 1.43
39 Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008 1.41
40 RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 2007 1.36
41 Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A 2011 1.36
42 Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004 1.35
43 Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 2006 1.34
44 Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology 2012 1.33
45 Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology 2004 1.33
46 Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 2009 1.31
47 E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008 1.29
48 Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 2010 1.28
49 Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver. Hepatology 2006 1.27
50 Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer. J Hepatol 2005 1.25
51 Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 2005 1.25
52 An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010 1.23
53 Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 2011 1.22
54 mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 2012 1.21
55 Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am J Pathol 2005 1.18
56 2-acetylaminofluorene dose-dependent differentiation of rat oval cells into hepatocytes: confocal and electron microscopic studies. Hepatology 2004 1.17
57 Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice. PLoS One 2010 1.17
58 The transcription factor GLI1 mediates TGFβ1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PLoS One 2012 1.17
59 Progenitor cells in liver regeneration: molecular responses controlling their activation and expansion. APMIS 2006 1.16
60 Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012 1.14
61 Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int J Cancer 2004 1.13
62 Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology 2003 1.12
63 Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 2005 1.09
64 The Icelandic Cancer Project--a population-wide approach to studying cancer. Nat Rev Cancer 2004 1.09
65 Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res 2011 1.09
66 Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res 2010 1.05
67 Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog 2011 1.05
68 Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis. J Biol Chem 2008 1.04
69 Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology 2003 1.03
70 Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin Liver Dis 2010 1.02
71 Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005 1.02
72 Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer 2011 1.02
73 Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 2013 1.02
74 Contribution of hepatic lineage stage-specific donor memory to the differential potential of induced mouse pluripotent stem cells. Stem Cells 2012 1.00
75 Genetic profiling of human hepatocellular carcinoma. Semin Liver Dis 2005 0.99
76 Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012 0.99
77 Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest 2014 0.97
78 Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013 0.97
79 E2F1 blocks and c-Myc accelerates hepatic ploidy in transgenic mouse models. Biochem Biophys Res Commun 2003 0.97
80 Activation of NF-kappaB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Hepatology 2004 0.95
81 Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab Invest 2004 0.95
82 Human homologue of maid is a useful marker protein in hepatocarcinogenesis. Gastroenterology 2005 0.95
83 Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro. Am J Pathol 2008 0.95
84 Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7). Gene 2002 0.94
85 Spontaneous differentiation of mouse embryonic stem cells in vitro: characterization by global gene expression profiles. Biochem Biophys Res Commun 2005 0.94
86 Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology 2006 0.94
87 Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital. Carcinogenesis 2004 0.93
88 Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways. Biochim Biophys Acta 2012 0.92
89 Dysregulation of DNA repair pathways in a transforming growth factor alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. Lab Invest 2003 0.91
90 Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res 2004 0.91
91 Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling. Physiol Genomics 2005 0.90
92 Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis 2003 0.89
93 Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling. J Korean Med Sci 2011 0.89
94 Enhanced tumor formation in cyclin D1 x transforming growth factor beta1 double transgenic mice with characterization by magnetic resonance imaging. Cancer Res 2004 0.88
95 Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas. Mol Cancer Res 2005 0.88
96 DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma. Int J Oncol 2003 0.88
97 ΔNp73β is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010 0.87
98 An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer. BMC Med Genomics 2013 0.87
99 SMAD5 gene expression, rearrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma. Neoplasia 2003 0.86
100 Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology 2014 0.86
101 Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis 2011 0.86
102 Oligonucleotide microarray analysis of aminoallyl-labeled cDNA targets from linear RNA amplification. Biotechniques 2004 0.85
103 Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer. J Hepatol 2004 0.84
104 Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes Dev 2013 0.84
105 Thyroid regeneration: characterization of clear cells after partial thyroidectomy. Endocrinology 2012 0.84
106 Genomic copy number alterations with transcriptional deregulation at 6p identify an aggressive HCC phenotype. Carcinogenesis 2013 0.83
107 Sall4 in "stemness"-driven hepatocarcinogenesis. N Engl J Med 2013 0.83
108 Triiodothyronine accelerates differentiation of rat liver progenitor cells into hepatocytes. Histochem Cell Biol 2008 0.83
109 Biphasic regulation of the NADPH oxidase by HGF/c-Met signaling pathway in primary mouse hepatocytes. Biochimie 2013 0.82
110 Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells. Stem Cell Res 2012 0.82
111 Linking MLL and the HGF-MET signaling pathway in liver cancer. J Clin Invest 2013 0.81
112 Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Carcinogenesis 2004 0.81
113 Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division. J Cancer 2013 0.81
114 Genomic decoding of hepatocellular carcinoma. Gastroenterology 2006 0.80
115 In vitro differentiation of rat liver derived stem cells results in sensitization to TNFalpha-mediated apoptosis. Hepatology 2004 0.80
116 CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines. Liver Int 2013 0.80
117 Hunting for tumor suppressor genes in liver cancer. Hepatology 2003 0.79
118 Acquired genetic and functional alterations associated with transforming growth factor beta type I resistance in Hep3B human hepatocellular carcinoma cell line. J Cell Mol Med 2009 0.78
119 Molecular constituents of the extracellular matrix in rat liver mounting a hepatic progenitor cell response for tissue repair. Fibrogenesis Tissue Repair 2013 0.78
120 Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease. Cancer Genet Cytogenet 2009 0.77
121 Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities. Gastroenterology 2013 0.76
122 Expression of stanniocalcin 1 in thyroid side population cells and thyroid cancer cells. Thyroid 2015 0.76
123 Genome-based predictors for HCC outcomes: a matter of tumor and/or stroma. J Hepatol 2009 0.75